Terminated PHASE1 INTERVENTIONAL 3-arm NCT01795950

Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)

A Phase I Safety and Pharmacodynamic Study of Intravenous Infusion of PLX-PAD Cells in Patients With PAH

Sponsor: United Therapeutics

Conditions Pulmonary Arterial Hypertension

Interventions PLX-PAD

Updated 5 times since 2017 Last updated: Feb 15, 2016 Started: Apr 30, 2013 Primary completion: Dec 31, 2015 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from United Therapeutics

See all terminations from United Therapeutics

Other Pulmonary Arterial Hypertension trials with similar outcome

Browse all Pulmonary Arterial Hypertension trials

This PHASE1 trial investigates Pulmonary Arterial Hypertension and is currently terminated or withdrawn. United Therapeutics leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

United Therapeutics

Data source: United Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brisbane, Australia
• Melbourne, Australia